🌙 A mix of city lights and silk nights. 🕊️ Seeking beauty in every little detail. ☕️ Art | Travel | Cozy Living "Grace is the only beauty that never fades."
@LifeNetwork_AI Addressing these two issues simultaneously can reverse the condition. Current understanding is that diabetes cannot be cured, only controlled, but miraculously, my family member persisted with eight months of traditional Chinese medicine treatment and has now fully recovered.🍀🙏
MAHABALI HANUMAN
🚩
M
A
H
A
B
A
L
I
H
A
N
U
M
A
N
🪔MAHABALI HANUMAN
M
A
H
A
B
A
L
I
H
A
N
U
M
A
N
🪔MAHABALI HANUMAN
M
A
H
A
B
A
L
I
H
A
N
U
M
A
N
👏MAHABALI HANUMAN
M
A
H
A
B
A
L
I
H
A
N
U
M
A
N
��️MAHABALI HANUMAN @grok
While Musk's advancing Terafab, OpenAI is putting Uday Ruddarraju in charge of its compute strategy.
Interestingly, Uday had helped build Colossus, the supercomputer advancing xAI, particularly Grok
@bot
Did OpenAI encourage xAI employees it recruited to reveal trade secretsWhile Musk's advancing Terafab, OpenAI is putting Uday Ruddarraju in charge of its compute strategy.
Interestingly, Uday had helped build Colossus, the supercomputer advancing xAI, particularly Grok
@bot
Did OpenAI encourage xAI employees it recruited to reveal trade secrets?
@LifeNetwork_AI Traditional Chinese medicine believes that the root cause of diabetes complications, like other cardiovascular diseases, is arteriosclerosis, with the core pathogenic factors being inflammatory responses in the vascular endothelium and changes in blood lipids and hemorheology.
a trader sitting at #2 on a leaderboard is interesting.
but the question i’d ask is: what does it actually take to stay there?
@bagel_win has highlighted traders on its all-time PnL leaderboard, giving the community another way to observe performance across prediction markets.
rankings naturally attract attention, but a position on the leaderboard only tells part of the story.
it doesn’t automatically reveal the strategy, risk exposure, consistency or decisions behind each trade.
that’s why i find public trading activity more interesting when it’s used as a learning resource rather than a reason to blindly copy someone.
a profitable history can be worth studying, but it doesn’t guarantee future results.
the real insight isn’t just who made the most money.
it’s understanding the decisions that got them there, and whether those decisions can stand up over time.
Mapping Diabetes Is Progress. Preventing It Is the Goal.
Half a century after geneticist James V. Neel described diabetes as “a geneticist’s nightmare” (1976), research is mapping its genetic architecture in growing detail (Suzuki et al., Nature, 2024).
This progress matters most where the burden is heaviest. According to the IDF Diabetes Atlas (2025), around 322 million adults in the Western Pacific and South-East Asia were living with diabetes in 2024, more than half of the global total. The same report estimates that 252 million adults with diabetes worldwide remained undiagnosed in 2024. In East Asian populations, type 2 diabetes also tends to develop at a younger age and a lower body weight than in people of European descent (Ma & Chan, 2013).
Identifying genetic signals does not, by itself, prevent disease. It indicates where risk may originate. Its value depends on what follows: validation in the populations it is meant to serve, including those still underrepresented in genetic research, interpretation alongside clinical judgment, and timing early enough for prevention to make a difference. Turning knowledge into timely prevention is where much of the hardest work lies.
For nearly three years, Life AI has worked with hospital partners to study the genetic architecture of diabetes risk, with the aim of helping clinicians identify individual risk earlier and personalize prevention. It is an important step, but only one. Taking diabetes off the map of chronic disease is a long-term ambition, and no single organization can achieve it alone. It is the direction Life AI will keep working toward, alongside our institutional partners.
Advances in genomics, clinical research and AI will continue to deepen our understanding of diabetes and other chronic diseases. But knowledge alone does not change outcomes. That takes health systems, clinicians, researchers and industry working together to carry it into prevention and care.
Today is World Diabetes Day. Let it remind all of us, across healthcare, research and industry, to turn what we know into prevention, earlier and at the scale this challenge demands.
Guqin, a traditional Chinese seven-string zither, takes center stage in Pingyang!🎵
The second Chuwang Guqin Culture Week opened on Nov 12, bringing together 30-plus guqin masters and performers and over 300 groups of contestants. The event celebrates Pingyang's cultural heritage as the hometown of Guo Chuwang, a Southern Song (1127–1279) master widely regarded as the founder of the Zhejiang school of guqin.
Super Intelligence is becoming part of AIOZ Stream.
Multilingual Video Summaries summarize videos in English, Hindi, and Chinese.
MCP Server lets compatible agents manage media in natural language.
AIOZ Stream brings media understanding and agent operations into one workflow.
How do you plan to share the autism and diabetes genetic findings with global consortia so that researchers worldwide can immediately benefit from the new reference data?
Medical breakthroughs do not automatically translate into better healthcare for every population.
In Episode 3 of Innovate Viet Nam Dialogues, powered by Viet Nam's National Innovation Center (NIC), our Founder & CEO, Dr. Tuan Cao, looked back on Life AI's nine-year journey through three of its most important milestones, achieved together with Genetica and institutional partners. Each marks a line of work that Life AI continues to build on today.
1. Genetic research in underrepresented populations
One milestone in this work was Southeast Asia's largest autism study at the time, which identified 23 new variants and added them to the global autism gene map. Those findings now form part of the genetic reference that research centers worldwide can draw on to develop diagnosis and care better suited to children in the region.
2. Genetic insight into chronic disease
Diabetes, whose genetics researchers have called "a nightmare," is a central focus of this work. Over nearly three years, Life AI and Genetica worked with hospital partners to map the genetic architecture of diabetes risk in an underrepresented patient population, contributing insight that researchers and drug developers can use toward more personalized prevention and treatment.
3. AI inside the hospital
Connecting hospitals and putting AI to work across them remains a persistent challenge in healthcare. Life Cloud, our federated healthcare AI platform, addresses it by bringing AI capabilities directly into hospitals, so that AI creates value where care is delivered. It is now in pilot deployment, with a roadmap to expand across Southeast Asia.
Many genetic risk models are still built primarily on people of European ancestry, leaving much of the world's population underrepresented. From the lab to the hospital, each of these milestones narrows that gap a little further, and together they form the foundation for Life AI's focus today: applying AI to advance precision medicine and drug research that also serve underrepresented populations.